{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:16:57Z","timestamp":1788239817150,"version":"build-2803163510"},"reference-count":203,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Poly-ADP-ribose polymerase (PARP) inhibitors represent a novel class of anticancer agents that leverage the principle of synthetic lethality to induce tumor cell death by disrupting defective DNA repair pathways. PARP inhibitors have demonstrated strong preclinical activity in tumors with homologous recombination (HR) repair deficiencies. The discovery of synthetic lethality between HR defects and PARP inhibition led to multiple clinical trials, first in BRCA1\/2-mutated cancers and later in other HR-deficient tumors. PARP inhibitors have become essential components of first- and later-line therapies for breast, prostate, pancreatic, and ovarian cancers, with several agents already approved by the FDA. However, their therapeutic potential in other malignancies remains less defined, as limited studies have explored their efficacy in additional solid tumors. This article provides an updated overview of PARP inhibitors use beyond their established clinical indications, highlighting current evidence, combination strategies, and emerging perspectives that may expand their role in various cancer treatment including endometrial cancer, cervical cancer, kidney cancer, colorectal cancer, non\u2013small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and other malignancies.<\/jats:p>","DOI":"10.3389\/fcell.2026.1891797","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:53Z","timestamp":1788236813000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies"],"prefix":"10.3389","volume":"14","author":[{"given":"Abdelhak","family":"Ouhajjou","sequence":"first","affiliation":[{"name":"Al-Azhar Oncology Center","place":["Rabat, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omayma","family":"Mazouji","sequence":"additional","affiliation":[{"name":"GES-LCM2E, FSA, Mohamed First University","place":["Nador, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakib","family":"Nejjari","sequence":"additional","affiliation":[{"name":"Euromed Research Center, Euromed University of Fes","place":["Fes, Morocco"]},{"name":"Faculty of Medicine, Pharmacy, and Dentistry, Sidi Mohamed Ben Abdellah University","place":["Fes, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Incitti","sequence":"additional","affiliation":[{"name":"Euromed Research Center, Euromed University of Fes","place":["Fes, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Mansour","sequence":"additional","affiliation":[{"name":"GES-LCM2E, FSA, Mohamed First University","place":["Nador, Morocco"]},{"name":"Euromed Research Center, Euromed University of Fes","place":["Fes, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"TRITON2 investigators. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration","volume":"38","author":"Abida","year":"","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study","volume":"26","author":"Abida","year":"","journal-title":"Clin. Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jtho.2021.04.001","article-title":"Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study","volume":"16","author":"Ai","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"10771","DOI":"10.3390\/ijms241310771","article-title":"Homologous Recombination Deficiency (HRD) in Cutaneous Oncology","volume":"24","author":"Akinjiyan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/ph18060905","article-title":"PARP Inhibition in Colorectal Cancer-A Comparison of Potential Predictive Biomarkers for Therapy","volume":"18","author":"Alfahed","year":"2025","journal-title":"Pharm. (Basel)."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1552386","DOI":"10.3389\/fonc.2025.1552386","article-title":"PARP inhibitors in melanoma treatment: potential, challenges, and future directions","volume":"15","author":"Anaeme","year":"2025","journal-title":"Front. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41698-025-01179-y","article-title":"Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer","volume":"9","author":"Arce-Gallego","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cllc.2021.02.009","article-title":"A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)","volume":"22","author":"Argiris","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.2014.60.0320","article-title":"Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer","volume":"33","author":"Bang","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"17588359221126149","DOI":"10.1177\/17588359221126149","article-title":"Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial","volume":"14","author":"Barretina-Ginesta","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-21-3045","article-title":"Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer","volume":"28","author":"Batalini","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdu581","article-title":"Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced\/metastatic pancreatic cancer","volume":"26","author":"Bendell","year":"2015","journal-title":"Ann. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"189221","DOI":"10.1016\/j.bbcan.2024.189221","article-title":"Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer","volume":"1879","author":"Bi","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"939570","DOI":"10.3389\/fphar.2022.939570","article-title":"Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development","volume":"13","author":"Bisht","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"17588359231221337","DOI":"10.1177\/17588359231221337","article-title":"Development of PARP inhibitors in advanced prostate cancer","volume":"16","author":"Bourlon","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/ijgc-2020-esgo.124","article-title":"Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by brcawt status: prima\/ENGOT-OV26\/GOG-3012 study","volume":"30","author":"Braicu","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/PPO.0000000000000554","article-title":"PARP Inhibitors in Pancreatic Cancer","volume":"27","author":"Brown","year":"2021","journal-title":"Cancer J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-20-4259","article-title":"Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Na\u00efve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study","volume":"27","author":"Byers","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.3390\/cancers14163877","article-title":"Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance","volume":"14","author":"Cahuzac","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41416-023-02534-1","article-title":"NCI10066: a Phase 1\/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma","volume":"130","author":"Cecchini","year":"2024","journal-title":"Br. J. Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s12282-026-01856-1","article-title":"Niraparib in breast cancer: evidence-based perspective on translational progress","volume":"33","author":"Chauhan","year":"2026","journal-title":"Breast Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","article-title":"Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer","volume":"10","author":"Christie","year":"2019","journal-title":"Nat. Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"13145","DOI":"10.1002\/cam4.5997","article-title":"Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results","volume":"12","author":"Ciardiello","year":"2023","journal-title":"Cancer Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1038\/onc.2017.40","article-title":"PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma","volume":"36","author":"Colicchia","year":"2017","journal-title":"Oncogene"},{"key":"B32","doi-asserted-by":"publisher","first-page":"A76","DOI":"10.1136\/ijgc-2020-esgo.130","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III SOLO1 study","volume":"30","author":"Colombo","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-023-01488-0","article-title":"PARP Inhibitors in Breast Cancer: a Short Communication","volume":"26","author":"Daly","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1\/2 Mutations and Selected Sporadic Cancers","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.3390\/ijms26062773","article-title":"Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy","volume":"26","author":"De","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer","volume":"27","author":"De Haan","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1158\/1535-7163.MCT-23-0724","article-title":"Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness","volume":"25","author":"Di Costanzo","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"113580","DOI":"10.1016\/j.ejca.2024.113580","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial","volume":"200","author":"Di\u00e9ras","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.tig.2014.06.003","article-title":"Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches","volume":"30","author":"Dietlein","year":"2014","journal-title":"Trends Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"699","DOI":"10.7150\/jca.90371","article-title":"Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions","volume":"15","author":"Dong","year":"2024","journal-title":"J. Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1200\/JCO.2023.41.16_suppl.5548","article-title":"Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1\/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"41","author":"Drescher","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/1535-7163.MCT-14-0276","article-title":"The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias","volume":"14","author":"Falzacappa","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2017.08.006","article-title":"PD-1\/PD-L1 and immunotherapy for pancreatic cancer","volume":"407","author":"Feng","year":"2017","journal-title":"Cancer Lett."},{"key":"B49","doi-asserted-by":"publisher","first-page":"101595","DOI":"10.1016\/j.eclinm.2022.101595","article-title":"Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial","volume":"52","author":"Fennell","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"17588359241255174","DOI":"10.1177\/17588359241255174","article-title":"PARP inhibitors in non-ovarian gynecologic cancers","volume":"16","author":"Fernandes","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1470-2045(21)00098-X","article-title":"Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial","volume":"22","author":"Friedlander","year":"2021","journal-title":"Lancet Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/1078-0432.CCR-25-3767","article-title":"Phase I\/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent\/Refractory Malignancies: Arm D of the AcS\u00e9-ESMART Trial","volume":"32","author":"Gatz","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e2400406","DOI":"10.1200\/PO-24-00406","article-title":"Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway- Deficient Neoplasms","volume":"8","author":"George","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"100231","DOI":"10.1016\/j.jtocrr.2021.100231","article-title":"Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene","volume":"2","author":"Ghafoor","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"81662","DOI":"10.18632\/oncotarget.20953","article-title":"Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers","volume":"8","author":"Glorieux","year":"2017","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ccell.2018.05.008","article-title":"Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality","volume":"33","author":"Gogola","year":"2018","journal-title":"Cancer Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cllc.2022.01.005","article-title":"Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","volume":"23","author":"Govindan","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/ijgc-2020-igcs.13","article-title":"Efficacy on individualized starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator-assessment (IA) in newly diagnosed advanced ovarian cancer (OC)","volume":"30","author":"Graybill","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e240133","DOI":"10.57264\/cer-2024-0133","article-title":"Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer","volume":"14","author":"Graybill","year":"2025","journal-title":"J. Comp. Eff. Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/nar\/gkx1208","article-title":"Acetylation of 53BP1 dictates the DNA double strand break repair pathway","volume":"46","author":"Guo","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1200\/JCO.2017.35.15_suppl.2022","article-title":"Results of the OPARATIC trial: A phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM)","volume":"35","author":"Halford","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/annonc\/mdz406","article-title":"Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib","volume":"30","author":"Hammel","year":"2019","journal-title":"Ann. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"LBA5506","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5506","article-title":"Durvalumab with Paclitaxel\/Carboplatin (PC) and Bevacizumab (Bev), Followed by Maintenance Durvalumab, Bev, and Olaparib in Patients (Pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC) without a Tumor BRCA1\/2 Mutation (Non-tBRCAm): Results from the Randomized, Placebo (Pbo)-Controlled Phase III DUO-O Trial","volume":"41","author":"Harter","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero","year":"2024","journal-title":"Genome Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/cancers16050932","article-title":"PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer","volume":"16","author":"Hirschl","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ygyno.2022.04.016","article-title":"A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium","volume":"166","author":"Jackson","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","article-title":"Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials","volume":"7","author":"Javle","year":"2021","journal-title":"JAMA Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2542358","DOI":"10.1080\/14756366.2025.2542358","article-title":"Structure-based design of new potent and highly selective PARP-1 inhibitor for treating colorectal cancer","volume":"40","author":"Jiang","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1038\/s41467-025-62678-x","article-title":"Maintenance olaparib after platinum-based chemotherapy for advanced\/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial","volume":"16","author":"Joly","year":"2025","journal-title":"Nat. Commun."},{"key":"B76","doi-asserted-by":"publisher","first-page":"eaav4508","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jtho.2024.10.021","article-title":"Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929","volume":"20","author":"Karim","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3390\/jcm15020685","article-title":"Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone","volume":"15","author":"Kawczak","year":"2026","journal-title":"J. Clin. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12885-022-10319-7","article-title":"The potential of PARP as a therapeutic target across pediatric solid malignancies","volume":"23","author":"Keller","year":"2023","journal-title":"BMC Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.annonc.2020.10.602","article-title":"Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?","volume":"32","author":"Khaddour","year":"","journal-title":"Ann. Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"a006129","DOI":"10.1101\/mcs.a006129","article-title":"Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency","volume":"7","author":"Khaddour","year":"","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1435056","DOI":"10.3389\/fonc.2024.1435056","article-title":"A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal\/gastroesophageal junction\/proximal gastric adenocarcinoma","volume":"14","author":"Khalid","year":"2024","journal-title":"Front. Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.2217\/fon-2021-0899","article-title":"Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003","volume":"17","author":"Kim","year":"2021","journal-title":"Future Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-22-3715","article-title":"Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer","volume":"29","author":"Kim","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.euo.2023.10.017","article-title":"A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer","volume":"7","author":"Kotecha","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2021.06.028","article-title":"Veliparib in combination with carboplatin\/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer","volume":"159","author":"Kozono","year":"2021","journal-title":"Lung Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"S786","DOI":"10.1016\/j.annonc.2022.07.655","article-title":"Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): defining benefit according to disease risk subgroups within the phase 3 ATHENA\u2013MONO study","volume":"33","author":"Kristeleit","year":"2022","journal-title":"Ann. Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.annonc.2025.10.007","article-title":"Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO\/GOG-3020\/ENGOT-ov45 study","volume":"37","author":"Kristeleit","year":"2026","journal-title":"Ann. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/IGC.0000000000000380","article-title":"A phase I-II evaluation of veliparib (NSC#737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology\/Gynecologic Oncology Group study","volume":"25","author":"Kunos","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"186","DOI":"10.56875\/2589-0646.1033","article-title":"PARP Inhibitors for the Treatment of BRCA1\/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis","volume":"16","author":"Kunwor","year":"2023","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.3390\/cancers14164050","article-title":"Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?","volume":"14","author":"Lazo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00280-023-04506-x","article-title":"PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials","volume":"91","author":"Li","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"10732748241298329","DOI":"10.1177\/10732748241298329","article-title":"Update on Combination Strategies of PARP Inhibitors","volume":"31","author":"Lin","year":"2024","journal-title":"Cancer Control."},{"key":"B97","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","article-title":"Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib","volume":"83","author":"Loehr","year":"2023","journal-title":"Eur. Urol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.tranon.2019.04.007","article-title":"Overexpressed ABCB1 Induces Olaparib-Taxane Cross- Resistance in Advanced Prostate Cancer","volume":"12","author":"Lombard","year":"2019","journal-title":"Transl. Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1053\/j.seminoncol.2023.09.003","article-title":"PARP inhibitors for prostate cancer","volume":"51","author":"Longoria","year":"2024","journal-title":"Semin. Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.004","article-title":"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma","volume":"89","author":"Lowery","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"B103","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s12276-022-00809-w","article-title":"PBK drives PARP inhibitor resistance through the TRIM37\/NF\u03baB axis in ovarian cancer","volume":"54","author":"Ma","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1182\/blood-2018-02-834895","article-title":"Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors","volume":"132","author":"Maifrede","year":"2018","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3390\/cancers18040560","article-title":"PARP Inhibitors Combined with Abiraterone Overcome Resistance in Metastatic Castration-Resistant Prostate Cancer Independently of Androgen Receptor","volume":"18","author":"Mallah","year":"2026","journal-title":"Cancers"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/jco.2019.37.15_suppl.5005","article-title":"TOPARP-B: a phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations","volume":"37","author":"Mateo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"880643","DOI":"10.3389\/fonc.2022.880643","article-title":"Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors","volume":"12","author":"Mekonnen","year":"2022","journal-title":"Front. Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737140.2026.2695214","article-title":"Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine","volume":"2","author":"Mercinelli","year":"2026","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.3390\/cancers16203447","article-title":"PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience","volume":"16","author":"Miao","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B111","doi-asserted-by":"publisher","first-page":"S340","DOI":"10.1016\/j.jid.2025.10.434","article-title":"425 PARP1\u2013p63 Axis as a Therapeutic Vulnerability in Cutaneous Squamous Cell Carcinoma","volume":"145","author":"Missero","year":"2025","journal-title":"Journal Investigative Dermatology"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","article-title":"PARP Inhibitors for Breast Cancer Treatment: A Review","volume":"10","author":"Morganti","year":"2024","journal-title":"JAMA Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/OTT.S499226","article-title":"The Landscape of PARP Inhibitors in Solid Cancers","volume":"18","author":"Muzzana","year":"2025","journal-title":"Onco Targets Ther."},{"key":"B117","unstructured":"Cl\u00ednicaltrials.gov\n          \n          \n          2025"},{"key":"B118","unstructured":"Clinicaltr\u00edals.gov\n          \n          \n          2025"},{"key":"B119","unstructured":"Clin\u00edcaltrials.gov\n          \n          \n          2017"},{"key":"B120","unstructured":"Cl\u00eenicaltrials.gov\n          \n          \n          2025"},{"key":"B121","unstructured":"Clin\u00eecaltrials.gov\n          \n          \n          2026"},{"key":"B122","unstructured":"Clinicaltr\u00eeals.gov\n          \n          \n          2024"},{"key":"B123","unstructured":"Cl\u00efnicaltrials.gov\n          \n          \n          2026"},{"key":"B124","unstructured":"Clin\u00efcaltrials.gov\n          \n          \n          2026"},{"key":"B125","unstructured":"Clinicaltr\u00efals.gov\n          \n          \n          2025"},{"key":"B126","unstructured":"Cl\u0129nicaltrials.gov\n          \n          \n          2022"},{"key":"B127","unstructured":"Clin\u0129caltr\u0129als.gov\n          \n          \n          2021"},{"key":"B128","unstructured":"Clinicaltrials.g\u00f6v\n          \n          \n          2025"},{"key":"B129","unstructured":"Clinicaltr\u0129als.g\u00f6v\n          \n          \n          2026"},{"key":"B130","unstructured":"Cl\u00efnicaltrials.g\u00f6v\n          \n          \n          2025"},{"key":"B131","unstructured":"Clinicaltrials.g\u00f4v\n          \n          \n          2025"},{"key":"B132","unstructured":"Clinicaltr\u00efals.g\u00f4v\n          \n          \n          2021"},{"key":"B133","unstructured":"Clinicaltrials.g\u00f3v\n          \n          \n          2025"},{"key":"B134","unstructured":"Clin\u00efcaltrials.g\u00f3v\n          \n          \n          2026"},{"key":"B135","unstructured":"Clinicaltrials.g\u00f2v\n          \n          \n          2026"},{"key":"B136","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/s12885-016-2656-8","article-title":"An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma","volume":"16","author":"Nile","year":"2016","journal-title":"BMC Cancer"},{"key":"B137","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP Inhibitors in Ovarian Cancer: A Review","volume":"18","author":"O'Malley","year":"2023","journal-title":"Target Oncol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA\/PALB2 Mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.18.00264","article-title":"Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive- Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04299-5","article-title":"Pembrolizumab and olaparib in homologous-recombination- deficient metastatic pancreatic cancer: the phase 2 POLAR trial","volume":"25","author":"Park","year":"2026","journal-title":"Nat. Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"17588359251411096","DOI":"10.1177\/17588359251411096","article-title":"Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study","volume":"18","author":"Peng","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"key":"B146","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41698-024-00684-w","article-title":"Efficacy of PARP inhibitor therapy after targeted BRAF\/MEK failure in advanced melanoma","volume":"8","author":"Phillipps","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41698-024-00634-6","article-title":"Phase II study of talazoparib in advanced cancers with BRCA1\/2, DNA repair, and PTEN alterations","volume":"8","author":"Piha-Paul","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"SOLO2\/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.3390\/ijms26157350","article-title":"Combination Therapy Using Phytochemicals and PARP Inhibitors in Hybrid Nanocarriers: An Optimistic Approach for the Management of Colon Cancer","volume":"26","author":"Qureshi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B151","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/cncr.33885","article-title":"JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer","volume":"128","author":"Ramalingam","year":"2022","journal-title":"Cancer"},{"key":"B152","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","article-title":"Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression","volume":"15","author":"Rathkey","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12609-025-00582-5","article-title":"Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors","volume":"17","author":"Ray","year":"2025","journal-title":"Curr. Breast Cancer Rep."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1056\/NEJMc1711644","article-title":"Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","article-title":"Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/ncb3626","article-title":"EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation","volume":"19","author":"Rondinelli","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"108058","DOI":"10.1016\/j.phrs.2025.108058","article-title":"Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer","volume":"222","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"B162","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","article-title":"PARP Inhibition in Cancer: An Update on Clinical Development","volume":"14","author":"Sachdev","year":"2019","journal-title":"Targ. Oncol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/1878-0261.70148","article-title":"Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107","volume":"20","author":"Schmitz","year":"2026","journal-title":"Mol. Oncol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/cimb47080638","article-title":"Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment","volume":"47","author":"Shah","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1631\/jzus.B2400146","article-title":"Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies","volume":"27","author":"Shoaib","year":"2025","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00316","article-title":"Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious Mutation","author":"Shroff","year":"2018","journal-title":"JCO Precis. Oncol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.3390\/cancers13215328","article-title":"PARP Inhibitors and Haematological Malignancies-Friend or Foe?","volume":"13","author":"Skelding","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B168","doi-asserted-by":"publisher","first-page":"102923","DOI":"10.1016\/j.ebiom.2020.102923","article-title":"Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity","volume":"59","author":"Smeby","year":"2020","journal-title":"EBioMedicine"},{"key":"B169","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1158\/1078-0432.CCR-14-2572","article-title":"Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program","volume":"21","author":"Smith","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B170","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1017\/erm.2020.3","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expert Rev. Mol. Med."},{"key":"B171","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"a006223","DOI":"10.1101\/mcs.a006223","article-title":"Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant","volume":"8","author":"Soon","year":"2022","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"B173","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/cancers15112885","article-title":"Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges","volume":"15","author":"Sorrentino","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/biom13101480","article-title":"Combination Treatment Strategies to Overcome PARP Inhibitor Resistance","volume":"13","author":"Soung","year":"2023","journal-title":"Biomolecules"},{"key":"B175","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s43018-022-00400-2","article-title":"Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer","volume":"3","author":"Spring","year":"2022","journal-title":"Nat. Cancer"},{"key":"B176","doi-asserted-by":"publisher","first-page":"37080","DOI":"10.18632\/oncotarget.26354","article-title":"A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"B177","doi-asserted-by":"publisher","first-page":"968060","DOI":"10.3389\/fphar.2022.968060","article-title":"Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.canlet.2021.11.005","article-title":"Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC","volume":"526","author":"Sun","year":"2022","journal-title":"Cancer Lett."},{"key":"B179","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.molcel.2017.09.036","article-title":"Restoration of Replication Fork Stability in BRCA1-and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers","volume":"68","author":"Taglialatela","year":"2017","journal-title":"Mol. Cell"},{"key":"B180","doi-asserted-by":"publisher","first-page":"oyaf283","DOI":"10.1093\/oncolo\/oyaf283","article-title":"PARP inhibitors in gastric cancer: unlocking precision oncology","volume":"30","author":"Tai","year":"2025","journal-title":"Oncologist"},{"key":"B181","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/annonc\/mdw635","article-title":"A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)","volume":"28","author":"Thaker","year":"2017","journal-title":"Ann. Oncol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","article-title":"A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance","volume":"32","author":"Tobalina","year":"2021","journal-title":"Ann. Oncol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"e1526","DOI":"10.1002\/onco.13829","article-title":"Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications","volume":"26","author":"Toh","year":"2021","journal-title":"Oncologist"},{"key":"B184","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","article-title":"A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer","volume":"40","author":"Tuli","year":"2019","journal-title":"EBioMedicine"},{"key":"B185","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1158\/1078-0432.CCR-21-0310","article-title":"Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG\/BIG5-13\/TESARO PR-30-50-10-C BRAVO Study","volume":"27","author":"Turner","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B186","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Olympia clinical trial steering committee and investigators adjuvant olaparib for patients with BRCA1 or BRCA2, mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B187","doi-asserted-by":"publisher","first-page":"105048","DOI":"10.1016\/j.critrevonc.2025.105048","article-title":"Effectiveness and safety of PARP inhibitors in breast cancer: An umbrella review of systematic reviews and meta-analyses","volume":"217","author":"Tzang","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.18632\/oncotarget.23386","article-title":"Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells","volume":"9","author":"Valdez","year":"2017","journal-title":"Oncotarget"},{"key":"B190","doi-asserted-by":"publisher","first-page":"11592","DOI":"10.18632\/oncotarget.24294","article-title":"MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models","volume":"9","author":"Vena","year":"2018","journal-title":"Oncotarget"},{"key":"B192","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann. Oncol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.radonc.2015.03.028","article-title":"Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells","volume":"116","author":"Verhagen","year":"2015","journal-title":"Radiother. Oncol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"115329","DOI":"10.1016\/j.ejca.2025.115329","article-title":"Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis","volume":"220","author":"Villacampa","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"B195","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s43556-025-00385-1","article-title":"PARPs and PARP inhibitors: molecular mechanisms and clinical applications","volume":"6","author":"Wang","year":"2025","journal-title":"Mol. Biomed."},{"key":"B196","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s12276-026-01673-8","article-title":"PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge","volume":"58","author":"Wang","year":"2026","journal-title":"Exp. Mol. Med."},{"key":"B197","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41388-024-03207-w","article-title":"Enhancing low-dose radiotherapy efficacy with PARP inhibitors via FBL-mediated oxidative stress response in colorectal cancer","volume":"44","author":"Wen","year":"2025","journal-title":"Oncogene"},{"key":"B198","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lungcan.2022.07.007","article-title":"Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial","volume":"171","author":"Woll","year":"2022","journal-title":"Lung Cancer"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-19-2549","article-title":"EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B200","doi-asserted-by":"publisher","first-page":"e734","DOI":"10.1097\/CAD.0000000000001160","article-title":"Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report","volume":"33","author":"Wu","year":"2022","journal-title":"Anticancer Drugs"},{"key":"B201","doi-asserted-by":"publisher","first-page":"9732","DOI":"10.18632\/oncotarget.6947","article-title":"PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response","volume":"7","author":"Wurster","year":"2016","journal-title":"Oncotarget"},{"key":"B202","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40364-026-00908-0","article-title":"Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective","volume":"14","author":"Xiang","year":"2026","journal-title":"Biomark. Res."},{"key":"B203","doi-asserted-by":"publisher","first-page":"2171783","DOI":"10.1080\/01443615.2023.2171783","article-title":"Anti-tumour and radiosensitising effects of PARP inhibitor on cervical cancer xenografts","volume":"43","author":"Xue","year":"2023","journal-title":"J. Obstet. Gynaecol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"1175617","DOI":"10.3389\/fonc.2023.1175617","article-title":"Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer","volume":"13","author":"Yang","year":"2023","journal-title":"Front. Oncol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/1471-0528.17324","article-title":"Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability","volume":"129","author":"Yuan","year":"2022","journal-title":"BJOG"},{"key":"B207","doi-asserted-by":"publisher","first-page":"102815","DOI":"10.1016\/j.ctrv.2024.102815","article-title":"Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review","volume":"130","author":"Zambelli","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"B208","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41523-025-00859-z","article-title":"Real-world effectiveness of PARP inhibitors after CDK4\/6 inhibitor therapy in BRCA-mutated HR-positive\/HER2-negative advanced breast cancer","volume":"11","author":"Zattarin","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B209","doi-asserted-by":"publisher","first-page":"102410","DOI":"10.1016\/j.tranon.2025.102410","article-title":"Therapeutic advances and application of PARP inhibitors in breast cancer","volume":"57","author":"Zhou","year":"2025","journal-title":"Transl. Oncol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"688","DOI":"10.6004\/jnccn.2022.7102","article-title":"Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity","volume":"21","author":"Zhou","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B211","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1158\/0008-5472.CAN-23-0401","article-title":"SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer","volume":"83","author":"Zhou","year":"2023","journal-title":"Cancer Res."},{"key":"B212","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","article-title":"PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications","volume":"19","author":"Zhu","year":"2020","journal-title":"Mol. Cancer"},{"key":"B213","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.1038\/s41467-021-27291-8","article-title":"Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma","volume":"12","author":"Zoumpoulidou","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1891797\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:58Z","timestamp":1788236818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1891797\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":203,"alternative-id":["10.3389\/fcell.2026.1891797"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1891797","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1891797"}}